文献速递肝病

通过持续氨输注量化人体氨清除与生成:肝硬化及靶向氨治疗的影响

Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments.
PubMed 文献 · J Hepatol · 2023-04-13

研究对10名健康男性和10名男性肝硬化患者进行90分钟持续氨输注,量化全身氨清除与生成,并验证甘油苯丁酸酯和乳果糖+利福昔明的作用。结果显示肝硬化患者氨清除降低20%而生成增加近三倍;苯丁酸酯使清除增加11%,乳果糖+利福昔明使生成减少20%。

要点

  • 肝硬化患者氨清除较健康人降低20%,生成增加近三倍。
  • 苯丁酸酯使健康人氨清除增加11%,乳果糖+利福昔明使肝硬化患者氨生成减少20%。
  • 持续氨输注法可分别量化全身氨清除与生成。

核心结论

  • 全身氨清除与生成可用所述持续氨输注技术分别测量。
  • 该技术发现肝硬化患者氨清除降低而生成增加,苯丁酸酯增加清除,乳果糖+利福昔明减少生成。

研究设计与样本

  • 研究纳入10名健康男性和10名男性肝硬化患者,进行90分钟持续氨输注以达到稳态血浆氨。
  • 全身氨清除按输注速率除以稳态浓度增幅计算,氨生成按清除乘以基线氨浓度计算。
  • 参与者在靶向氨干预后再次接受检查。

主要发现

  • 健康人氨清除为3.5(3.1-3.9)L/min,氨生成49(35-63)μmol/min。
  • 苯丁酸酯使清除增加11%(4-19%,p=0.009)。
  • 肝硬化患者氨清除降低20%,为2.7(2.1-3.3)L/min(p=0.02),生成增至近三倍,为131(102-159)μmol/min(p<0.0001)。
  • 乳果糖+利福昔明使生成减少20%(2-37%,p=0.03)。
  • 输注总体耐受良好,仅一例高氨血症肝硬化患者出现可能与出血无关的临床肝性脑病,停止输注后恢复。

临床怎么用

  • 所述测试可用于研究正常生理、病理生理及靶向氨治疗作用机制的相关问题。

局限性

  • 仅一例高氨血症肝硬化患者出现临床肝性脑病,该患者可能出血且与输注无关,停输注后恢复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hyperammonaemia is a key pathological feature of liver disease and the primary driver of hepatic encephalopathy (HE). However, the relative roles of increased ammonia production and reduced clearance are poorly understood as is the action of ammonia-targeting drugs for HE. We aimed to quantify whole-body ammonia metabolism in healthy persons and patients with cirrhosis and to validate our method by examining the effects of glycerol phenylbutyrate and lactulose + rifaximin treatment. METHODS: Ten healthy men and ten male patients with cirrhosis were investigated by 90-minute constant ammonia infusion to achieve steady-state plasma ammonia. Whole-body ammonia clearance was calculated as infusion rate divided by steady-state concentration increase and ammonia production was calculated as clearance multiplied by baseline ammonia concentration. Participants were re-investigated after the ammonia-targeting interventions. RESULTS: In healthy persons, ammonia clearance was 3.5 (3.1-3.9) L/min and ammonia production was 49 (35-63) μmol/min. Phenylbutyrate increased clearance by 11% (4-19%, p = 0.009). In patients with cirrhosis, ammonia clearance was 20% lower at 2.7 (2.1-3.3) L/min (p = 0.02) and production was nearly threefold higher at 131 (102-159) μmol/min (p <0.0001). Lactulose + rifaximin reduced production by 20% (2-37%, p = 0.03). The infusion was generally well-tolerated apart from in one hyperammonaemic patient, with cirrhosis and possible bleeding unrelated to the infusion, who developed clinical HE that reverted when infusion was discontinued. CONCLUSIONS: Whole-body ammonia clearance and production may be measured separately using the described technique. This technique identified a lower clearance and a higher production of ammonia in patients with cirrhosis, and showed that phenylbutyrate increases clearance, whereas lactulose + rifaximin reduces production. IMPACT AND IMPLICATIONS: High blood ammonia plays a key role in cirrhosis-related brain dysfunction. However, the relative roles of reduced ammonia clearance and increased ammonia production are poorly understood as is the action of ammonia-targeting treatments. This study presents a relatively simple test to measure ammonia metabolism. By using this test, it was possible to show that patients with cirrhosis exhibit decreased ammonia clearance and increased ammonia production compared to healthy persons, and to quantify the unique effects of different ammonia-targeting treatments. The test described herein may be used to examine a range of questions related to normal physiology, pathophysiology and the mechanisms of action of ammonia-targeting treatments. CLINICAL TRIAL NUMBER: ClinicalTrials.gov (1-16-02-297-20).

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Eriksen PL, Djernes L, Vilstrup H, et al. Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments. J Hepatol. 2023. PMID: 37061198. doi:10.1016/j.jhep.2023.03.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。